| Drug General Information |
| Drug ID |
D0W7JZ
|
| Former ID |
DNCL002107
|
| Drug Name |
Tivozanib
|
| Synonyms |
ASP4130/AV-951
|
| Drug Type |
Small molecular drug
|
| Indication |
Renal cancer [ICD9: 140-229, 189; ICD10:C64]
|
Phase 3 |
[1],
[2]
|
|---|
| Company |
Astellas Pharma US; AVEO Pharmaceuticals
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C22H19ClN4O5
|
| InChI |
InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
|
| InChIKey |
SPMVMDHWKHCIDT-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
14882223, 24192058, 45983488, 78829796, 99302829, 99437027, 99453618, 123051118, 123087413, 123110210, 124490423, 124757081, 124955473, 125163885, 125570998, 126659904, 126731226, 131480730, 135261059, 135685196, 135685197, 135685214, 135685972, 135685973, 135685994, 135685995, 136340121, 136367363, 136920274, 137262648, 139498427, 143499542, 144115647, 144187404, 152234928, 152258283, 152344393, 160647122, 162011363, 162037498, 162201687, 163685747, 170484711, 170496628, 170502198, 172914257, 174560995, 175607447, 177748705, 178102679
|
| Target and Pathway |
| Target(s) |
Vascular endothelial growth factor receptor 1 |
Target Info |
Inhibitor |
[2]
|
|---|
| Vascular endothelial growth factor receptor 3 |
Target Info |
Modulator |
[3]
|
| Vascular endothelial growth factor receptor 2 |
Target Info |
Modulator |
[3]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
HIF-1 signaling pathway
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Focal adhesion
|
|
Transcriptional misregulation in cancer
|
|
Rheumatoid arthritishsa04014:Ras signaling pathway
|
|
Focal adhesionhsa04014:Ras signaling pathway
|
|
VEGF signaling pathway
|
|
Proteoglycans in cancer
|
|
NetPath Pathway
|
TNFalpha Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
Glypican 1 network
|
|
HIF-2-alpha transcription factor network
|
|
S1P3 pathway
|
|
VEGF and VEGFR signaling network
|
|
VEGFR1 specific signals
|
|
Signaling events mediated by VEGFR1 and VEGFR2vegf_vegfr_pathway:VEGF and VEGFR signaling network
|
|
VEGFR3 signaling in lymphatic endotheliumhif2pathway:HIF-2-alpha transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
S1P1 pathway
|
|
Integrins in angiogenesis
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Notch-mediated HES/HEY network
|
|
Reactome
|
Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerizationR-HSA-195399:VEGF binds to VEGFR leading to receptor dimerizationR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerization
|
|
Integrin cell surface interactions
|
|
EPHA-mediated growth cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
VEGFR2 mediated cell proliferation
|
|
WikiPathways
|
Focal Adhesion
|
|
Signaling by VEGF
|
|
AngiogenesisWP1919:Signaling by VEGFWP306:Focal Adhesion
|
|
Nifedipine Activity
|
|
Cardiac Progenitor Differentiation
|
|
Angiogenesis
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01076010) An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib Versus Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301). U.S. National Institutes of Health. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6058). |
|---|
| REF 3 | Clinical pipeline report, company report or official report of AVEO Pharmaceuticals. |
|---|
